This letter to the editor summarises a study used to assess the impact of erythropoiesis-stimulating agents (ESA) treatment on overall survival and on the evolution of MDS into acute myeloid leukaemia.
Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator
MDS Factsheet for GPs General Practicioners
Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.
This is an external link to the home of the British Society for Haematology (BSH).